Clinical characteristics for de novo acute myeloid leukemia with normal karyotype (AML-NK) patients stratified by the level of BCL2, BAX gene expression and BAX/BCL2 ratio
| Parameter | BCL2 | BAX | BAX/BCL2 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total n=51 | BCL2+ n=25 | BCL2− n=26 | P | BAX+ n=25 | BAX− n=26 | P | BAX/BCL2high n=25 | BAX/BCL2low n=26 | P | |
| Sex | ||||||||||
| Male (%) | 26 (51) | 10 (38) | 16 (62) | 0.165 | 16 (62) | 10 (38) | 0.095 | 16 (62) | 10 (38) | 0.095 |
| Female (%) | 25 (49) | 15 (60) | 10 (40) | 9 (36) | 16 (64) | 9 (36) | 16 (64) | |||
| Age* (years) | 51 (23–62) | 53 (27–62) | 49 (23–62) | 0.137 | 49 (27–62) | 52.5 (23–62) | 0.597 | 48 (23–62) | 54 (27–62) | 0.111 |
| WBC count* (×109/L) | 22 (1–349) | 7 (1–184) | 22.5 (2–349) | 0.159 | 22 (1–184) | 22 (0.2–349) | 0.808 | 29 (1–349) | 6 (1–184) | 0.041 |
| HB* (g/L) | 99 (66–131) | 103 (82–131) | 98 (66–128) | 97 (66–131) | 105 (78–128) | 98 (66–128) | 103 (82–131) | |||
| > 80 (g/L) | 45 (88) | 25 (56) | 20 (44) | 0.023 | 22 (49) | 23 (51) | 1.000 | 19 (53) | 26 (47) | |
| < 80 (g/L) | 6 (12) | 0 | 6 (100) | 3 (50) | 3 (50) | 0 | 6 (100) | 0.010 | ||
| Plts* (×109/L) | 55 (8–422) | 60 (8–422) | 53.5 (8–169) | 0.528 | 55 (17–169) | 54.5 (8–422) | 0.497 | 52 (8–169) | 60 (8–422) | 0.685 |
| LDH *(U/L) | 321 (1–2904) | 175 (153–1992) | 590.5 (1–2904) | 0.010 | 386 (153–1992) | 306.5 (1–2904) | 0.816 | 605 (1–2904) | 75 (153–1992) | 0.002 |
| PB blast* (%) | 14 (0–98) | 15 (0–98) | 11 (0–97) | 0.737 | 11 (0–92) | 16 (0–98) | 0.623 | 11 (0–97) | 15 (0–98) | 0.865 |
| BM blasts* (%) | 62 (30–97) | 57 (30–90) | 66.5 (32–90) | 0.531 | 63 (30–97) | 61 (31–90) | 0.756 | 70 (30–90) | 57 (31–97) | 0.341 |
| CD34 (%) | 0.095 | 0.404 | 0.050 | |||||||
| present | 24 (47) | 15 (63) | 9 (38) | 10 (42) | 14 (58) | 8 (33) | 16 (67) | |||
| absent | 27 (53) | 10 (37) | 17 (363) | 15 (56) | 12 (44) | 17 (63) | 10 (37) | |||
| FAB (%) | 0.006 | 0.239 | 0.002 | |||||||
| M0 | 4 (8) | 4 (100) | 0 | 1 (25) | 3 (75) | 0 | 4 (100) | |||
| M1 | 5 (10) | 4 (80) | 1 (20) | 3 (60) | 2 (40) | 1 (20) | 4 (80) | |||
| M2 | 18 (35) | 10 (56) | 8 (44) | 7 (39) | 11 (62) | 6 (33) | 12 (67) | |||
| M4 | 17 (33) | 3 (18) | 14 (82) | 8 (47) | 9 (53) | 14 (82) | 3 (18) | |||
| M5 | 7 (14) | 4 (57) | 3 (43) | 6 (86) | 1 (14) | 4 (57) | 3 (43) | |||
| CR (%) | 0.404 | 0.264 | 0.577 | |||||||
| success | 28(55) | 12 (43) | 16 (57) | 16 (57) | 12 (43) | 15 (54) | 13 (46) | |||
| failure | 23(45) | 13 (57) | 10 (43) | 9 (39) | 14 (61) | 10 (43) | 13 (57) | |||
| Resistance (%) | 0.024 | 0.703 | 0.044 | |||||||
| yes | 8 (16) | 7 (88) | 1 (12) | 3 (38) | 5 (62) | 1 (13) | 7 (87) | |||
| no | 43 (84) | 18 (42) | 25 (58) | 22 (51) | 21 (49) | 24 (56) | 19 (44) | |||
| Relapse (%) | 1.000 | 0.047 | 0.137 | |||||||
| yes | 17 (61) | 7 (41) | 10 (59) | 7 (41) | 10 (59) | 7 (41) | 10 (59) | |||
| no | 11 (39) | 5 (45) | 6 (55) | 9 (82) | 2 (18) | 8 (73) | 3 (27) | |||
| FLT3-ITD mutations (%) | 0.324 | 1.000 | 0.199 | |||||||
| present | 12 (24) | 4 (33) | 8 (67) | 6 (50) | 6(50) | 8 (67) | 4 (33) | |||
| absent | 39 (76) | 21 (54) | 18 (46) | 19 (49) | 20 (51) | 17 (44) | 22 (56) | |||
| NPM1 mutations (%) | 0.237 | 0.144 | 0.144 | |||||||
| present | 17 (33) | 6 (35) | 11 (65) | 11 (65) | 6 (35) | 11 (65) | 6 (35) | |||
| absent | 34 (67) | 19 (56) | 15 (44) | 14 (41) | 20 (59) | 14 (41) | 20 (59) | |||
Clinical characteristics for de novo acute myeloid leukemia with normal karyotype (AML-NK) patients stratified by the level of MDR1 gene expression
| Parameter | Total n=51 | MDR1+ n=26 | MDR1− n=25 | P |
|---|---|---|---|---|
| Sex | 0.051 | |||
| Male (%) | 26 (51) | 17 (65) | 9 (35) | |
| Female (%) | 25 (49) | 9 (36) | 16 (64) | |
| Age* (years) | 51 (23–62) | 53 (23–62) | 49 (23–62) | 0.396 |
| WBC count* (×109/L) | 22 (1–349) | 7 (1–184) | 26 (0–349) | 0.071 |
| Hemoglobin* (g/L) | 99 (66–131) | 106 (78–124) | 96 (66–131) | 0.191 |
| > 80 (g/L) | 45 (88) | 24 (53) | 21 (47) | |
| < 80 (g/L) | 6 (12) | 1 (17) | 5 (83) | |
| Platelets* (×109/L) | 55 (8–422) | 42 (8–422) | 69.5 (16–169) | 0.129 |
| LDH *(U/L) | 321 (1–2904) | 175 (1–2904) | 553.5 (175–1992) | 0.028 |
| PB blast* (%) | 14 (0–98) | 14 (0–98) | 13.5 (0–87) | 0.900 |
| BM blasts* (%) | 62 (30–97) | 57 (30–90) | 65 (33–97) | 0.565 |
| CD34 (%) | 0.025 | |||
| present | 24 (47) | 16 (67) | 8 (33) | |
| absent | 27 (53) | 9 (33) | 18 (67) | |
| FAB (%) | <0.001 | |||
| M0 | 4 (8) | 4 (100) | 0 | |
| M1 | 5 (10) | 5 (100) | 0 | |
| M2 | 18 (35) | 11 (61) | 7 (39) | |
| M4 | 17 (33) | 3 (18) | 14 (82) | |
| M5 | 7 (14) | 2 (29) | 5 (71) | |
| Complete remission (%) | 0.781 | |||
| success | 28(55) | 13 (46) | 15 (54) | |
| failure | 23(45) | 12 (52) | 11 (48) | |
| Resistance (%) | 1.000 | |||
| yes | 8 (16) | 4 (50) | 4 (50) | |
| no | 43 (84) | 21 (49) | 22 (51) | |
| Relapse (%) | 0.460 | |||
| yes | 17 (61) | 9 (53) | 8 (47) | |
| no | 11 (39) | 4 (36) | 7 (64) | |
| FLT3-ITD mutations (%) | 0.019 | |||
| present | 12 (24) | 2 (17) | 10 (83) | |
| absent | 39 (76) | 23 (59) | 16 (41) | |
| NPM1 mutations (%) | 0.075 | |||
| present | 17 (33) | 5 (29) | 12 (71) | |
| absent | 34 (67) | 20 (59) | 14 (41) | |
| BCL2+ | 25 (49) | 20 (80) | 5 (20) | <0.001 |
| BCL2− | 26 (51) | 5 (24) | 21 (76) | |
| BAX/BCL2high | 25(49) | 5 (20) | 20 (80) | |
| BAX/BCL2low | 26 (51) | 20 (77) | 6 (23) | <0.001 |